C&G Editor in Chief, Erin Harris

  1. Why In Vivo Innovation, Regulatory Convergence Will Help Shape CGT's Next Chapter 10/19/2026

    Connecting scientific advances with scalable manufacturing, rigorous evidence, and regulatory strategies can help bring therapies to patients.

  2. Inside The Next Phase In Autoimmune CAR T From Meeting On The Mesa 2026 10/12/2026

    At Meeting on the Mesa 2026, industry leaders discussed what it will take to move autoimmune CAR T beyond promising clinical results.

  3. What LSPA's Life Sciences Future Says About The Road Ahead For CGT 10/2/2026

    The LSPA’s Life Sciences Future 2026 highlighted how shifting capital, M&A, global competition, and commercial pressures are reshaping CGT.

  4. Inside Scaling Next-Gen MSCs Without Scaling Risk 9/25/2026

    Here's why scaling MSC therapies requires maintaining product consistency, potency, and comparability as manufacturing evolves.

  5. Inside Kyverna's Autoimmune CAR T Platform Beyond SPS 9/16/2026

    Kyverna's progress suggests that autoimmune CAR T's commercial viability will depend as much on manufacturing readiness and focused indication selection as on its potential to deliver durable, drug-free remission.

  6. Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions? 9/2/2026

    The promise of autoimmune CAR T is enormous, but recent safety pauses from Novartis and BMS underscore why the field needs a more patient-centered approach to risk, clinical outcomes, access, and real-world delivery.

  7. Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology 8/28/2026

    REVTORPYK's FDA approval highlights the broader push toward precision therapies that address complex disease biology, overcome resistance, and deliver more durable patient benefit.

  8. In Vivo CAR T Needs More Than Better Cell Engineering 8/26/2026

    In vivo CAR T’s potential to expand access and simplify manufacturing hinges on targeted LNP delivery and solving the durability challenge.

  9. Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs 8/20/2026

    CoRegen’s investigational autologous cell therapy, CRG-150, is designed to disrupt tumor-driven immune suppression by knocking out SRC-3 in Tregs, potentially exposing solid tumors to the patient’s own immune response without lymphodepletion.

  10. Building Antigen-Specific Immune Tolerance For Autoimmune Disease 8/10/2026

    Antigen-specific immune tolerance could redefine autoimmune disease treatment by precisely retraining the immune system rather than broadly suppressing it.